Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With...
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prosta...
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type ...
ImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Paym...
The world of drug discovery is about to get a major boost as two cutting-edge technologies join forces. The integration of Serengen's unrivalled DEL techno...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Abrysvo is administered as a single dose injection into the muscle. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...
TAE Life Sciences has announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino aci...
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today anno...
Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...
The approval of ELREXFIO (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study EL...
© 2025 Biopharma Boardroom. All Rights Reserved.
